Bdparib 300mg

Bdparib 300mg Tablet is a medication used to treat advanced ovarian cancer. Here are some key points about the product:

Composition:

Bdparib 300mg Tablet contains Rucaparib, a poly ADP-ribose polymerase (PARP) inhibitor.

Indications:

Bdparib 300mg Tablet is indicated for the treatment of:

1. Advanced ovarian cancer (AOC) in patients with germline or somatic BRCA mutations
2. Advanced ovarian cancer (AOC) in patients with other BRCA mutations, as well as in patients with other genetic mutations associated with BRCA deficiency
3. Maintenance treatment of ovarian cancer in patients who have not progressed after platinum-based chemotherapy

Mechanism of Action:

Rucaparib works by:

1. Inhibiting the activity of PARP, an enzyme involved in the repair of DNA damage
2. Reducing the ability of cancer cells to repair DNA damage, leading to increased sensitivity to chemotherapy
3. Inhibiting the growth and proliferation of cancer cells

Dosage and Administration:

The recommended dosage of Bdparib 300mg Tablet is:

• 300mg taken orally twice daily, with or without food
• Take at the same time each day

Side Effects:

Common side effects of Bdparib 300mg Tablet include:

1. Fatigue
2. Nausea
3. Vomiting
4. Diarrhea
5. Abdominal pain
6. Increased risk of infections

Serious side effects can include:

1. Hemolytic anemia (a type of blood disorder)
2. Thrombocytopenia (low platelet count)
3. Leukopenia (low white blood cell count)
4. Neutropenia (low neutrophil count)
5. Liver damage

Contraindications:

Bdparib 300mg Tablet is contraindicated in patients with:

1. Hypersensitivity to Rucaparib
2. Pregnancy or breastfeeding
3. Severe liver disease or liver impairment

Precautions:

1. Patients with a history of blood disorders or blood dyscrasias should be closely monitored while receiving Bdparib 300mg Tablet.
2. Patients with a history of liver disease or liver impairment should be closely monitored while receiving Bdparib 300mg Tablet.
3. Patients with a history of infection or immunosuppression should be closely monitored while receiving Bdparib 300mg Tablet.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of fatigue, nausea, or vomiting.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store bottles at room temperature between 15°C and 30°C (59°F and 86°F).
• Do not expose to direct sunlight or moisture.
• Use within 24 hours of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.